Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). Corporate presentation dated May 2026 furnished under Regulation FD.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Corporate presentation dated May 2026 furnished under Regulation FD
- Investor-relevant disclosures likely contained in Exhibit 99.1 presentation
- CEO Dipal Doshi signed the filing on May 18, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.